Xenetic Biosciences, Inc. (XBIO)
4.20
-0.08
(-1.87%)
USD |
NASDAQ |
Sep 09, 16:00
4.20
0.00 (0.00%)
After-Hours: 17:10
Xenetic Biosciences Enterprise Value : 3.557M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 3.557M |
| September 04, 2026 | 4.471M |
| September 03, 2026 | 4.377M |
| September 02, 2026 | 3.487M |
| September 01, 2026 | 3.440M |
| August 31, 2026 | 3.346M |
| August 28, 2026 | 2.854M |
| August 27, 2026 | 2.831M |
| August 26, 2026 | 2.573M |
| August 25, 2026 | 2.479M |
| August 24, 2026 | 2.456M |
| August 21, 2026 | 1.940M |
| August 20, 2026 | 1.472M |
| August 19, 2026 | 1.401M |
| August 18, 2026 | 1.144M |
| August 17, 2026 | 1.167M |
| August 14, 2026 | 1.214M |
| August 13, 2026 | 1.237M |
| August 12, 2026 | 1.261M |
| August 11, 2026 | 1.073M |
| August 10, 2026 | 0.7687M |
| August 07, 2026 | 0.9561M |
| August 06, 2026 | 0.2063M |
| August 05, 2026 | 0.4641M |
| August 04, 2026 | 0.1126M |
| Date | Value |
|---|---|
| August 03, 2026 | -0.2389M |
| July 31, 2026 | -0.5318M |
| July 30, 2026 | -0.4966M |
| July 29, 2026 | -0.6607M |
| July 28, 2026 | -0.6138M |
| July 27, 2026 | -0.6138M |
| July 24, 2026 | -0.2858M |
| July 23, 2026 | -0.1803M |
| July 22, 2026 | -0.2155M |
| July 21, 2026 | -0.1452M |
| July 20, 2026 | 0.1126M |
| July 17, 2026 | 0.047M |
| July 16, 2026 | 0.1126M |
| July 15, 2026 | 0.3235M |
| July 14, 2026 | 0.5578M |
| July 13, 2026 | 0.136M |
| July 10, 2026 | -0.0631M |
| July 09, 2026 | 0.0306M |
| July 08, 2026 | -0.1217M |
| July 07, 2026 | 0.30M |
| July 06, 2026 | 0.2063M |
| July 02, 2026 | 0.0189M |
| July 01, 2026 | 0.4172M |
| June 30, 2026 | 0.3469M |
| June 29, 2026 | -0.8162M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9297M |
| Revenue (Quarterly) | 0.6606M |
| Total Expenses (Quarterly) | 1.590M |
| EPS Diluted (Quarterly) | -0.4052 |
| Profit Margin (Quarterly) | -140.7% |
| Earnings Yield | -28.28% |
| Normalized Earnings Yield | -28.28 |